Researchers at the Max Planck Institute for Molecular Genetics have developed a novel synthetic micropeptide termed the ...

Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle. Tufts Center for the Study ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous ...

Monoclonal antibodies provide protection against a wide range of infectious microbes, and now, in a series of elegant ...

Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to ...

Cidara Therapeutics, a US biotech leveraging its Cloudbreak platform for next‑generation antivirals, saw its stock more than ...

SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according ...

In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, ...

Over the last 10 years, breakthroughs in understanding the genetic instructions passed from parent to offspring have put ...